MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
20.65
-1.18
-5.41%
Pre Market: 20.90 +0.25 +1.21% 05:50 08/13 EDT
OPEN
21.37
PREV CLOSE
21.83
HIGH
21.62
LOW
20.44
VOLUME
111
TURNOVER
0
52 WEEK HIGH
38.35
52 WEEK LOW
16.24
MARKET CAP
4.00B
P/E (TTM)
-15.2275
1D
5D
1M
3M
1Y
5Y
1D
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga · 17h ago
Legend Biotech Is Maintained at Overweight by Morgan Stanley
Dow Jones · 17h ago
Legend Biotech Price Target Raised to $49.00/Share From $48.00 by Morgan Stanley
Dow Jones · 17h ago
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49
Benzinga · 18h ago
Legend Biotech Is Maintained at Hold by TD Cowen
Dow Jones · 18h ago
Legend Biotech Price Target Cut to $24.00/Share From $29.00 by TD Cowen
Dow Jones · 18h ago
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24
Benzinga · 18h ago
Legend Biotech downgraded at Oppenheimer on CEO exit, competition
Seeking Alpha · 18h ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.